Tag: Sanofi

November 6, 2015 Off

Sanofi and Lexicon to develop sotagliflozin (for diabetics)

By Dino Mustafić

Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.

October 7, 2015 Off

Sanofi: New Analysis on Relapsing Multiple Sclerosis

By Dino Mustafić

Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).